Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02033928 · ClinicalTrials.gov registry record
Comprehensive Frailty Assessment
A clinical trial of Hematologic Neoplasms and Myeloma Multiple, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- 111
- Enrollment target
- 1
- Study location
NCT02033928: Completed study of Hematologic Neoplasms and Myeloma Multiple, sponsored by Ohio State University Comprehensive Cancer Center.
NCT02033928 is a study of Hematologic Neoplasms and Myeloma Multiple that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 111 participants, below the 1,021-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02033928, a study of Hematologic Neoplasms and Myeloma Multiple, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 111 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to describe a patients' fitness before and after treatment (whether that treatment be chemotherapy or a transplant). Fitness is a way of measuring a patient's current quality of health. With surveys, questionnaires and blood tests, we hope to create a tool that will give a good picture of patients' ability to tolerate treatment. In the future, we hope to devise the best treatment for a patient based on their "fitness".
Primary Outcome
Responses to the Comprehensive Frailty Assessment will be assessed before and after treatment and changes will be evaluated. In transplant patients, this will be measured one year post transplant and in the non-transplant arm, this will be assessed after the second cycle of treatment.
Conditions Studied
Study Locations (1)
Ohio
- The Ohio State University Hospital East - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2014-04 |
| Est. Completion | 2017-08 |
What the finished NCT02033928 record still lists
NCT02033928 is an observational study that tracks outcomes without assigning an intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 1,021-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with Hematologic Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT02033928 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02033928 about?
NCT02033928 is a clinical study titled "Comprehensive Frailty Assessment". The purpose of this research study is to describe a patients' fitness before and after treatment (whether that treatment be chemotherapy or a transplant). Fitness is a way of measuring a patient's current quality of health. With surveys, questionnaires and blood tests, we hope to create a tool that ...
What is the current status of trial NCT02033928?
This trial is currently completed. The enrollment target is 111 participants. The study started on 2014-04. Estimated completion is 2017-08.
What conditions does trial NCT02033928 study?
This clinical trial studies the following conditions: Hematologic Neoplasms, Myeloma Multiple, Paraproteinemias.
Who is sponsoring clinical trial NCT02033928?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02033928 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02033928's enrollment target sits among peer trials
111 9th of 20 higher than 12 of 20 other Hematologic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
RECRUITING
-
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
RECRUITING · NA
-
UWCCC Molecular Tumor Board Registry
RECRUITING
-
Cognitive Training Intervention and Attitudes Towards Genetics
RECRUITING · NA
-
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia